|Slideshows|July 28, 2017

New Insights on Substance Use Disorders

A clinical collection on addiction treatment, ADHD and SUDs, important drug indications, vaping, cannabis use, benzodiazepines, the perils of self-medicating and other topics relevant to practicing psychiatrists.

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Subscribe

Related Content

FDA Issues CRL for Cytisinicline for Smoking Cessation in Adults

ByJessica Walters

June 22nd 2026

Connecting REM Sleep and Substance Use Vulnerability

ByColleen McClung, PhD

June 19th 2026

Evidence-Based Nonpharmacological Interventions in Schizophrenia: Focus on Cognitive Impairment

ByAntonio Vita, MD, PhD,Gabriele Nibbio, MD, PhD,Stefano Barlati, MD

June 19th 2026

Treating Patients With First-Episode Psychosis: Lessons From McLean OnTrack

ByMichael Murphy, MD, PhD,Allison Nelson-Eliot, LICSW

June 18th 2026

Assessment of Suicide Risk in Individuals With Schizophrenia

ByCarla Kotzé, PhD, MMed, MPhil, FCPsych,Johannes Lodewikus Roos, MD, DSc, MMed, FCPsych

June 17th 2026

Latest CME

In-Person Event

Southern California Psychiatry Conference

July 10-11, 2026

Register now!

Video

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Video

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

John Koo, MD; T.J. Chao, MPAS, PA-C

Video

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Ilan Melnick, MD; Linda Collado, MD, DABPN, FAPA; Maria Collado, MD, FAPA

Video

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Patricia Junquera, MD; Maria Collado, MD; Erin C. Crown, MHSPAS, PA-C, Psych-CAQ

Video

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Juan D. Oms, MD, FAPA; Linda Collado, MD, DABPN, FAPA; Ginger Shupe, MD

New Insights on Substance Use Disorders

Related Content

FDA Issues CRL for Cytisinicline for Smoking Cessation in Adults

Connecting REM Sleep and Substance Use Vulnerability

Evidence-Based Nonpharmacological Interventions in Schizophrenia: Focus on Cognitive Impairment

Treating Patients With First-Episode Psychosis: Lessons From McLean OnTrack

Assessment of Suicide Risk in Individuals With Schizophrenia

Latest CME

Southern California Psychiatry Conference

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Trending on Psychiatric Times

New Positive Data From Largest Real-World Study of Deep TMS in Patients With Comorbid PTSD and MDD

Starting ADHD Treatment in Adolescents, With Ann Childress, MD

Podcast: Practical Insights Into the Evolving Treatment of Bipolar Disorder With David Dunner, MD, FACPsych

New Phase 3 Post Hoc Analyses of Centanafadine for the Treatment of Adults With ADHD

June 2026 in Review: Updates on the Psychiatric Treatment Pipeline